Published in Brain on October 01, 2012
SPG7 mutations are a common cause of undiagnosed ataxia. Neurology (2015) 1.66
Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol (2014) 1.52
Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain (2014) 1.49
Delving into the complexity of hereditary spastic paraplegias: how unexpected phenotypes and inheritance modes are revolutionizing their nosology. Hum Genet (2015) 1.09
Ophthalmic manifestations of inherited neurodegenerative disorders. Nat Rev Neurol (2014) 0.92
Loss of association of REEP2 with membranes leads to hereditary spastic paraplegia. Am J Hum Genet (2014) 0.90
Dominant optic atrophy, OPA1, and mitochondrial quality control: understanding mitochondrial network dynamics. Mol Neurodegener (2013) 0.89
Mitochondrial ribosome assembly in health and disease. Cell Cycle (2015) 0.88
Medical management of hereditary optic neuropathies. Front Neurol (2014) 0.86
Evidence for autosomal recessive inheritance in SPG3A caused by homozygosity for a novel ATL1 missense mutation. Eur J Hum Genet (2014) 0.86
Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet (2015) 0.85
Spastic paraplegia type 7 is associated with multiple mitochondrial DNA deletions. PLoS One (2014) 0.85
A neurodegenerative perspective on mitochondrial optic neuropathies. Acta Neuropathol (2016) 0.84
Genetic landscape remodelling in spinocerebellar ataxias: the influence of next-generation sequencing. J Neurol (2015) 0.83
Hereditary spastic paraplegia in Greece: characterisation of a previously unexplored population using next-generation sequencing. Eur J Hum Genet (2015) 0.81
Motor protein mutations cause a new form of hereditary spastic paraplegia. Neurology (2014) 0.80
A novel mutation of AFG3L2 might cause dominant optic atrophy in patients with mild intellectual disability. Front Genet (2015) 0.80
Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis. Mol Ther (2017) 0.79
Genome-wide expression profiling and functional characterization of SCA28 lymphoblastoid cell lines reveal impairment in cell growth and activation of apoptotic pathways. BMC Med Genomics (2013) 0.79
Genes and Pathways Involved in Adult Onset Disorders Featuring Muscle Mitochondrial DNA Instability. Int J Mol Sci (2015) 0.78
Early-onset optic neuropathy as initial clinical presentation in SPG7. J Neurol (2014) 0.78
Characterization of Alu and recombination-associated motifs mediating a large homozygous SPG7 gene rearrangement causing hereditary spastic paraplegia. Neurogenetics (2014) 0.77
Optical coherence tomography findings in Huntington's disease: a potential biomarker of disease progression. J Neurol (2015) 0.76
SPG7 mutations explain a significant proportion of French Canadian spastic ataxia cases. Eur J Hum Genet (2015) 0.76
Abnormal Paraplegin Expression in Swollen Neurites, τ- and α-Synuclein Pathology in a Case of Hereditary Spastic Paraplegia SPG7 with an Ala510Val Mutation. Int J Mol Sci (2015) 0.75
SPG7 and Impaired Emotional Communication. Cerebellum (2016) 0.75
Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell (1998) 4.41
The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. Cell (2005) 3.72
Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res (2010) 3.58
Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol (2008) 3.49
The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy 'plus' phenotype. Brain (2011) 3.04
Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet (2010) 2.66
Hereditary spastic paraplegias: membrane traffic and the motor pathway. Nat Rev Neurosci (2011) 2.30
An intersubunit signaling network coordinates ATP hydrolysis by m-AAA proteases. Mol Cell (2009) 2.12
Variable and tissue-specific subunit composition of mitochondrial m-AAA protease complexes linked to hereditary spastic paraplegia. Mol Cell Biol (2006) 2.00
Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. J Cell Biol (2003) 1.95
Paraplegin mutations in sporadic adult-onset upper motor neuron syndromes. Neurology (2008) 1.86
Hereditary spastic paraplegias: an update. Curr Opin Neurol (2007) 1.83
AAA proteases: cellular machines for degrading membrane proteins. Trends Biochem Sci (2000) 1.73
Membrane protein degradation by AAA proteases in mitochondria: extraction of substrates from either membrane surface. Mol Cell (2000) 1.73
Heterozygous OPA1 mutations in Behr syndrome. Brain (2010) 1.57
Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases. PLoS Genet (2011) 1.54
REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction. Hum Mutat (2011) 1.26
A new locus for autosomal recessive hereditary spastic paraplegia maps to chromosome 16q24.3. Am J Hum Genet (1998) 1.25
Visual system involvement in patients with Friedreich's ataxia. Brain (2008) 1.25
Translating m-AAA protease function in mitochondria to hereditary spastic paraplegia. Trends Mol Med (2006) 1.24
Autosomal recessive spastic paraplegia (SPG30) with mild ataxia and sensory neuropathy maps to chromosome 2q37.3. Brain (2006) 1.22
AAA proteases in mitochondria: diverse functions of membrane-bound proteolytic machines. Res Microbiol (2009) 1.22
Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia. Neurology (2006) 1.20
TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy. Am J Hum Genet (2009) 1.19
Emerging roles of mitochondrial proteases in neurodegeneration. Biochim Biophys Acta (2009) 1.19
Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. Eye (Lond) (2011) 1.17
A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain (2004) 1.11
Identification and characterization of AFG3L2, a novel paraplegin-related gene. Genomics (1999) 1.10
Functional evaluation of paraplegin mutations by a yeast complementation assay. Hum Mutat (2010) 1.09
Missense mutations in the AFG3L2 proteolytic domain account for ∼1.5% of European autosomal dominant cerebellar ataxias. Hum Mutat (2010) 1.08
A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Hum Mutat (2008) 1.06
Early onset and slow progression of SCA28, a rare dominant ataxia in a large four-generation family with a novel AFG3L2 mutation. Eur J Hum Genet (2010) 0.97
Paraplegin gene analysis in hereditary spastic paraparesis (HSP) pedigrees in northeast England. Neurology (2001) 0.93
SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clin Genet (2012) 0.91
A novel splice site mutation in the SPG7 gene causing widespread fiber damage in homozygous and heterozygous subjects. Mov Disord (2010) 0.87
A novel form of autosomal recessive hereditary spastic paraplegia caused by a new SPG7 mutation. Neurology (2007) 0.86
Hereditary spastic paraplegia caused by the novel mutation 1047insC in the SPG7 gene. J Neurol (2008) 0.79
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
NT5E mutations and arterial calcifications. N Engl J Med (2011) 8.71
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
Disruption of Bardet-Biedl syndrome ciliary proteins perturbs planar cell polarity in vertebrates. Nat Genet (2005) 4.76
Prevalence of mitochondrial DNA disease in adults. Ann Neurol (2008) 4.72
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol (2006) 4.05
Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med (2005) 3.88
Mitochondrial DNA mutations in human colonic crypt stem cells. J Clin Invest (2003) 3.84
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature (2010) 3.73
Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res (2010) 3.58
Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet (2009) 3.56
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol (2013) 3.56
Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet (2008) 3.56
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain (2011) 3.48
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain (2006) 3.16
Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood (2011) 3.16
Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat (2004) 3.07
TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet (2011) 3.06
Titin mutation segregates with hereditary myopathy with early respiratory failure. Brain (2012) 3.02
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol (2011) 2.99
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med (2006) 2.93
Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res (2002) 2.88
A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet (2008) 2.82
Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet (2004) 2.75
What causes mitochondrial DNA deletions in human cells? Nat Genet (2008) 2.70
BBS10 encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat Genet (2006) 2.68
Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet (2010) 2.66
Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol (2007) 2.61
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) (2004) 2.54
Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell (2010) 2.42
The epidemiology of mitochondrial disorders--past, present and future. Biochim Biophys Acta (2004) 2.41
Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background. Am J Hum Genet (2007) 2.40
Universal heteroplasmy of human mitochondrial DNA. Hum Mol Genet (2012) 2.39
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain (2009) 2.38
Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet (2006) 2.34
De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet (2012) 2.34
Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol (2012) 2.33
Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet (2005) 2.33
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol (2009) 2.30
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet (2003) 2.26
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet (2006) 2.24
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am J Hum Genet (2004) 2.22
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev (2011) 2.21
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
Genotyping microarray (disease chip) for Leber congenital amaurosis: detection of modifier alleles. Invest Ophthalmol Vis Sci (2005) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am J Hum Genet (2002) 2.17
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol (2012) 2.13
The phenotypic spectrum of SCN8A encephalopathy. Neurology (2015) 2.12
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet (2006) 2.09
Efficient mitochondrial biogenesis drives incomplete penetrance in Leber's hereditary optic neuropathy. Brain (2013) 2.08
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology (2013) 2.06
Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology (2012) 2.05
Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet (2006) 2.04
ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet (2008) 2.04
Spectrum of NPHP6/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype. Hum Mutat (2007) 2.04
Autosomal recessive cortical myoclonic tremor and epilepsy: association with a mutation in the potassium channel associated gene CNTN2. Brain (2013) 2.02
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am J Hum Genet (2006) 1.99